|
Bansil et al., 2015
|
VIA
|
77.1 (59.9–89.6)
|
47.3 (40.8–53.8)
|
17.8 (12.0–24.8)
|
93.3 (87.3–97.1)
|
93.8 (69.8–99.8)
|
60.5 (57.3–63.7)
|
3.9 (2.2–6.4)
|
99.8(99.0–100.0)
|
|
Chung et al., 2013
|
VIA
|
62.7 (53.4–71.2)
|
65.9 (60.7–70.7)
|
37.1 (30.5–44.2)
|
84.6 (79.8–88.5)
| | | | |
|
Dartell et al., 2014
|
VIA
|
50.0 (31.5–68.5)
|
90.5 (87.2–93.8)
|
32.6
|
95.2
|
22.9 (14.5–31.3)
|
97.2 (96.7–97.8)
|
21.6
|
97.5
|
|
Huchko et al., 2015
|
VIA
|
84.0 (64.0–95.5)
|
78.6 (73.5–83.1)
|
24.7 (16.0–35.3)
|
98.3 (95.8–99.5)
| | | | |
|
Joshi et al., 2013
|
VIA
|
83.6 (71.2–92.2)
|
88.8 (86.7–90.6)
|
27.7 (21.1–35.2)
|
99.1 (98.2–99.6)
| | | | |
|
Kuhn et al., 2010
|
VIA
|
63.9 (46.2–79.2)
|
73.5 (67.4–78.8)
|
27.5 (17.8–37.3)
|
90.9 (85.8–96.0)
|
47.8 (35.7–60.2)
|
80.3 (78.2–82.2)
|
9.6 (6.5–12.7)
|
96.7 (95.6–97.8)
|
|
Mabeya et al., 2012
|
VIA
|
69.6
|
51.0
|
38.6
|
79.1
| | | | |
|
Sahasrabuddhe et al., 2012
|
VIA
|
80.0 (66.3–90.0)
|
82.6 (77.4–87.1)
|
47.6 (36.6–58.9)
|
95.4 (91.8–97.8)
| | | | |
|
Akinwuntan et al., 2008
|
VIA
|
76.0 (52.0–91.0)
|
83.0 (77.0–88.0)
|
34.0 (21.0–49.0)
|
97.0 (92.0–99.0)
| | | | |
|
Firnhaber et al., 2016
|
VIA
|
65.4 (59.7–71.1)
|
68.5 (65.3–71.7)
| | | | | | |
|
Chibwesha et al., 2016
|
VIA
|
48.0 (30.0–67.0)
|
92.0 (86.0–95.0)
|
52.0 (33.0–71.0)
|
91.0 (85.0–95.0)
| | | | |
|
Huchko et al., 2015
|
VILI
|
84.2 (68.7–94.0)
|
76.4 (71.2–81.3)
|
31.7 (22.8–41.7)
|
97.4 (94.4–99.0)
| | | | |
|
Joshi et al., 2013
|
VILI
|
89.1 (77.8–95.9)
|
89.3 (87.3–91.1)
|
30.1 (23.1–37.7)
|
99.4 (98.6–99.8)
| | | | |
|
Chibwesha et al., 2016
|
DC
|
59.0 (41.0–76.0)
|
88.0 (82.0–93.0)
|
49.0 (32.0–65.0)
|
92.0 (87.0–96.0)
| | | | |
|
Bateman et al., 2014
|
DC
|
84.0 (72.0–91.0)
|
58.0 (52.0–64.0)
|
33.0 (26.0–41.0)
|
93.0 (88.0–96.0)
| | | | |
|
Joshi et al., 2013
|
Pap smear
|
63.3 (48.3–76.6)
|
94.5 (92.9–95.8)
|
35.2 (25.3–46.1)
|
98.2 (97.2–98.9)
| | | | |
|
Chung et al., 2013
|
Pap smear
|
71.8 (62.8–79.4)
|
97.1 (94.7–98.4)
|
88.8 (80.5–93.8)
|
91.5 (88.2–93.9)
| | | | |
|
Mabeya et al., 2013
|
Pap smear
|
52.5
|
66.3
|
39.7
|
76.8
| | | | |
|
Sahasrabuddhe et al., 2012
|
Pap smear
|
60.5 (44.4–75.0)
|
64.6 (57.9–70.8)
|
24.8 (16.9–34.1)
|
89.4 (83.6–93.7)
| | | | |
|
Akinwuntan et al., 2008
|
Pap smear
|
57.0 (34.0–77.0)
|
95.0 (90.0–97.0)
|
55.0 (33.0–75.0)
|
95.0 (91.0–98.0)
| | | | |
|
Firnhaber et al., 2013
|
Pap smear
|
75.8 (70.8–80.8)
|
83.4 (80.9–85.9)
| | | | | | |
|
Bateman et al., 2014
|
Pap smear
|
61.0 (48.0–72.0)
|
58.0 (52.0–64.0)
|
27.0 (20.0–35.0)
|
86.0 (79.0–90.0)
| | | | |
|
Michelow et al., 2016
|
Cellslide® automated liquid-based cytology
|
76.0 (64.8–85.1)
|
91.0 (87.0–94.2)
|
70.4 (59.2–80.0)
|
93.1 (89.4–95.9)
| | | | |
|
Bansil et al., 2015
|
Vaginal careHPV
|
80.0 (63.1–91.6)
|
59.9 (53.4–66.2)
|
22.8 (15.7–31.2)
|
95.3 (90.6–98.1)
|
75.0 (47.6–92.7)
|
81.9 (79.3–84.4)
|
6.7 (3.5–11.4)
|
99.5 (98.7–99.9)
|
|
Bansil et al., 2015
|
Cervical careHPV
|
94.3 (80.8–99.3)
|
62.4 (55.9–68.6)
|
27.0 (19.4–35.8)
|
98.7 (95.3–99.8)
|
81.3 (54.4–96.0)
|
80.9 (78.2–83.3)
|
6.8 (3.7–11.4)
|
99.6 (98.8–99.9)
|
|
Obiri-Yeboah et al., 2017
|
CareHPV
|
87.5 (47.3–99.7)
|
52.1 (44.7–59.5)
|
7.2 (3.0–14.3)
|
99.0 (94.5–100.0)
| | | | |
|
Segondy et al., 2016 [36]
|
CareHPV
|
93.3 (83.8–98.2)
|
57.9 (54.5–61.2)
| | | | | | |
|
Chung et al., 2013
|
HPV DNA test
|
83.6 (75.6–89.4)
|
55.7 (50.4–60.9)
|
37.7 (31.9–43.9)
|
91.4 (86.8–94.5)
| | | | |
|
Dartell et al., 2014
|
HR HPV
|
100.0
|
58.2 (52.6.63.7)
|
17.9
|
100.0
|
92.7 (87.5–97.9)
|
85.3 (84.0–86.6)
|
17.2
|
99.7
|
|
Joshi et al., 2013
|
HC2 test
|
94.6 (84.9–98.9)
|
77.4 (74.8–79.9)
|
17.8 (13.6–22.6)
|
99.6 (99.0–99.9)
| | | | |
|
Ngou et al., 2015
|
HC2
|
88.8
|
55.2
|
24.7
|
96.7
| | | | |
|
Ngou et al., 2015
|
INNO-LiPA
|
92.5
|
35.1
|
19.1
|
96.6
| | | | |
|
Obiri-Yeboah et al., 2017
|
Anyplex II HPV 28
|
87.5 (47.3–99.7)
|
38.8 (31.8–46.2)
|
5.7 (2.3–11.5)
|
98.6 (92.7–100.0)
| | | | |
|
Firnhaber et al., 2016
|
HC2
|
91.9 (88.5–95.3)
|
51.4 (48.0–54.8)
| | | | | | |
|
Chibwesha et al., 2016
|
Xpert HPV
|
88.0 (71.0–97.0)
|
60.0 (52.0–86.0)
|
30.0 (21.0–40.0)
|
96.0 (90.0–99.0)
| | | | |
|
Chibwesha et al., 2016
|
OncoE6
|
31.0 (16.0–50.0)
|
99.0 (97.0–100)
|
91.0 (59–100)
|
88.0 (83.0–93.0)
| | | | |
|
Segondy et al., 2016
|
INNO-LiPA
|
96.7 (88.5–99.6)
|
32.0 (29.0–35.2)
| | | | | | |
|
Kuhn et al., 2010
|
HPV DNA
|
94.4 (81.3–99.3)
|
64.4 (58.0–70.3)
|
29.9 (21.3–38.6)
|
97.2 (87.0–99.4)
|
87.0 (76.7–93.9)
|
87.0 (85.2–88.6)
|
22.7(17.6–27.9)
|
99.0 (97.9–99.5)
|
|
Wu et al., 2016
|
P16INK4a cutoff level = 9 U/mL (%)
|
89.0
|
22.9
|
13.6
|
93.8
| | | | |
|
Chung et al., 2013
|
VIA + HPV test
|
58.2 (48.8–67.0)
|
83.7 (79.4–87.2)
|
53.3 (44.4–62.0)
|
86.2 (82.1–89.5)
| | | | |
|
Chung et al., 2013
|
VIA + Pap smear
|
50.9 (41.7–60.1)
|
99.1 (97.5–99.7)
|
94.9 (86.1–98.3)
|
86.3 (82.5–89.3)
| | | | |
|
Chung et al., 2013
|
HPV + Pap smear
|
62.7 (53.4–71.2)
|
98.5 (96.6–99.4)
|
93.2 (85.1–97.1)
|
89.2 (85.7–91.9)
| | | | |
|
Joshi et al., 2013
|
VIA and VILI
|
81.8 (69.1–90.9)
|
93.2 (91.5–94.6)
| | | | | | |
|
Joshi et al., 2013
|
HC2 and VIA
|
80.0 (67.0–89.6)
|
96.0 (94.6–97.1)
| | | | | | |
|
Joshi et al., 2013
|
HC2 and VILI
|
83.6 (71.2–92.2)
|
96.9 (95.7–97.9)
| | | | | | |
|
Joshi et al., 2013
|
HC2 and VIA/VILI
|
85.5 (73.3–93.5)
|
95.3 (93.9–96.5)
| | | | | | |
|
Joshi et al., 2013
|
VIA and cytology
|
57.1 (42.2–71.2)
|
98.8 (98.0–99.4)
| | | | | | |
|
Joshi et al., 2013
|
VILI and cytology
|
55.1 (40.2–69.3)
|
99.6 (99.0–99.9)
| | | | | | |
|
Joshi et al., 2013
|
HC2 and cytology
|
63.3 (48.3–76.6)
|
96.6 (95.3–97.6)
| | | | | | |
